Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)


30 Sep 2019


Poster Display session 3


Tumour Site

Renal Cell Cancer


Sophie Hans


Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249


S. Hans1, A. simonaggio1, K. Hamidatou1, L. Fournier2, C. Thibault1, R. Elaidi3, S. Oudard1, Y. Vano4

Author affiliations

  • 1 Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 2 Radiology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3 Medical Oncolgy, ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, 75015 - Paris/FR
  • 4 Service D'oncologie Médicale, Hôpital Européen Georges Pompidou, 75015 - Paris/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5268


N is a standard of care for patients with mccRCC after failure of a TKI. Nevertheless, nearly 45% of pts had a progressive disease (PD) as best response and PFS was disappointing. In this study we sought to describe a “real-world” cohort of pts with mRCC treated with N beyond first progression to identify factors predicting a clinical benefit.


We included in a retrospective study all consecutive mRCC pts who received at least one N injection at a French single-center between 2013 and 2018. Clinical and biological data were collected prospectively. Radiological evaluations were done by CT-scan using iRECIST. Characteristics of pts who with unconfirmed PD (iuPD) were described and compared according to the continuation of N beyond iuPD or not. Pts with a clinical benefit (CB) (objective response (OR=CR+PR) or stable disease (SD)) from N post-iuPD, were compared with pts with icPD as best response (BOR) post-iuPD.


109 patients were included, 84% had a clear cell histology; IMDC’s favorable, intermediate and poor prognostic groups at N initiation were 21%, 52% and 27%, respectively. After a median follow-up of 24.4 months [14.9-NA], median PFS and OS were 6.03 months [4.6-10] and 25.8 months [24.2-30.1] respectively. ORR was 18.4% (3.7% CR) and 74 pts experienced a first iuPD, including 5 clinical PD. Among the 69 radiological iUPD, 12 had new lesions (16%), 32 had progression of pre-existing lesions (43%) and 25 had both (33%). 36 pts (49%) received N beyond PD. Responses post-iuPD were 3 (4%) PR, 14 (19%) SD and 17 (23%) icPD.; they were more frequently ECOG-PS 0-1 (86% versus 47%, p = 0.0005), had better IMDC group (FAV+INT = 86% vs 53%, p = 0.01) and had higher lymphocyte count (p = 0.04). 17/18 (48%) pts had a CB with N post-iuPD, with a better OS than those without CB (31.8 months vs 24.9 months, p = 0.02). The only factor associated with the absence of CB were LDH>200 (p = 0.038).


We report the largest analysis of treatment with N beyond progression in a real world cohort of mRCC supporting that pseudo-progression is a rare event (4%). We show also that treatment beyond progression is very common (49%) and that LDH>200 might be the better ready-to-use predictive factor of a lack of CB.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yann-Alexandre Vano.


Has not received any funding.


L. Fournier: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Janssen; Speaker Bureau / Expert testimony: Sanofi; Research grant / Funding (institution): Invectys; Research grant / Funding (institution): Philips; Research grant / Funding (institution): Evolucare; Research grant / Funding (institution): ArianaPharma; Research grant / Funding (institution): Imagia. C. Thibault: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer. Y. Vano: Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Roche; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Pfizer MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Merck; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Astellas. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.